536 related articles for article (PubMed ID: 19265619)
1. Cutaneous manifestation of disseminated strongyloidiasis in a patient coinfected with HTLV-I.
Arch EL; Schaefer JT; Dahiya A
Dermatol Online J; 2008 Dec; 14(12):6. PubMed ID: 19265619
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis.
Carvalho EM; Da Fonseca Porto A
Parasite Immunol; 2004; 26(11-12):487-97. PubMed ID: 15771684
[TBL] [Abstract][Full Text] [Related]
3. Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases.
Peters L; McCarthy AE; Faught C
Int J Infect Dis; 2009 Nov; 13(6):e501-3. PubMed ID: 19501008
[TBL] [Abstract][Full Text] [Related]
4. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin.
Marty FM; Lowry CM; Rodriguez M; Milner DA; Pieciak WS; Sinha A; Fleckenstein L; Baden LR
Clin Infect Dis; 2005 Jul; 41(1):e5-8. PubMed ID: 15937753
[TBL] [Abstract][Full Text] [Related]
5. [Recurrent strongyloidiasis as an indicator of HTLV-1 infection].
Richter J; Schwarz U; Duwe S; Ellerbrok H; Poggensee G; Pauli G
Dtsch Med Wochenschr; 2005 Apr; 130(16):1007-10. PubMed ID: 15830313
[TBL] [Abstract][Full Text] [Related]
6. Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case report.
Ashida C; Kinoshita K; Nozaki Y; Funauchi M
BMC Infect Dis; 2020 Jul; 20(1):470. PubMed ID: 32615937
[TBL] [Abstract][Full Text] [Related]
7. Impairment of host immune response against strongyloides stercoralis by human T cell lymphotropic virus type 1 infection.
Hirata T; Uchima N; Kishimoto K; Zaha O; Kinjo N; Hokama A; Sakugawa H; Kinjo F; Fujita J
Am J Trop Med Hyg; 2006 Feb; 74(2):246-9. PubMed ID: 16474078
[TBL] [Abstract][Full Text] [Related]
8. Atypical clinical presentation of strongyloidiasis in a patient co-infected with human T cell lymphotrophic virus type I.
Porto MA; Alcântara LM; Leal M; Castro N; Carvalho EM
Am J Trop Med Hyg; 2005 Feb; 72(2):124-5. PubMed ID: 15741545
[TBL] [Abstract][Full Text] [Related]
9. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis.
Turner SA; Maclean JD; Fleckenstein L; Greenaway C
Am J Trop Med Hyg; 2005 Nov; 73(5):911-4. PubMed ID: 16282302
[TBL] [Abstract][Full Text] [Related]
10. Disseminated Strongyloides stercoralis infection with a cutaneous presentation in an immunosuppressed patient.
Benvenuti F; Carrascosa JM; Boada A; Ferrandiz C
Eur J Dermatol; 2009; 19(4):404-5. PubMed ID: 19467975
[No Abstract] [Full Text] [Related]
11. [An overview of Strongyloides stercoralis and its infections].
Ardiç N
Mikrobiyol Bul; 2009 Jan; 43(1):169-77. PubMed ID: 19334396
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Strongyloides stercoralis infection: an unusual presentation.
Ly MN; Bethel SL; Usmani AS; Lambert DR
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl Case Reports):S157-60. PubMed ID: 12894109
[TBL] [Abstract][Full Text] [Related]
13. Disseminated Strongyloidiasis.
Mileo Bacelar Guerreiro F; Tavares Sodré C; Brandão Pavan L; Feijó Barroso P; Carvalho Quintella D; Cuzzi T; Ramos-E-Silva M
Acta Dermatovenerol Croat; 2018 Dec; 26(4):333-336. PubMed ID: 30665485
[TBL] [Abstract][Full Text] [Related]
14. Severe and treatment resistant strongyloidiasis--indicator of HTLV-I infection.
Jeyamani R; Joseph AJ; Chacko A
Trop Gastroenterol; 2007; 28(4):176-7. PubMed ID: 18416349
[TBL] [Abstract][Full Text] [Related]
15.
Hashiba Y; Umekita K; Minami H; Kawano A; Nagayasu E; Maruyama H; Hidaka T; Okayama A
Mod Rheumatol Case Rep; 2021 Jan; 5(1):16-21. PubMed ID: 32772699
[TBL] [Abstract][Full Text] [Related]
16. Case Report:
De Souza JN; Soares BNRR; Goes LL; Lima CS; Barreto NMPV; Jacobina BS; Gonçalves N; Teixeira MCA; Galvão-Castro B; Grassi MFR; Soares NM
Am J Trop Med Hyg; 2018 Dec; 99(6):1583-1586. PubMed ID: 30277207
[No Abstract] [Full Text] [Related]
17. Cutaneous manifestations of Strongyloides stercoralis hyperinfection in an HIV-seropositive patient.
Martin SJ; Cohen PR; MacFarlane DF; Grossman ME
Skinmed; 2011; 9(3):199-202. PubMed ID: 21675505
[TBL] [Abstract][Full Text] [Related]
18. Case report: failure of subcutaneous ivermectin in treating Strongyloides hyperinfection.
Leung V; Al-Rawahi GN; Grant J; Fleckenstein L; Bowie W
Am J Trop Med Hyg; 2008 Dec; 79(6):853-5. PubMed ID: 19052292
[TBL] [Abstract][Full Text] [Related]
19. Treatment of strongyloidiasis in HTLV-1 and Strongyloides stercoralis coinfected patients is associated with increased TNFα and decreased soluble IL2 receptor levels.
Salles F; Bacellar A; Amorim M; Orge G; Sundberg M; Lima M; Santos S; Porto A; Carvalho E
Trans R Soc Trop Med Hyg; 2013 Aug; 107(8):526-9. PubMed ID: 23843560
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary strongyloidiasis.
Jayaprakash B; Sandhya S; Anithakumari K
J Assoc Physicians India; 2009 Jul; 57():535-6. PubMed ID: 20329418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
